Emergence of Cortical Amyloid from the Prodromal Stage of the Lewy Body Disease Spectrum: Evidence from a PiB-PET Study
Objective: To characterize β-amyloid (Aβ) deposition across the Lewy body disease (LBD) spectrum using Pittsburgh compound B positron emission tomography (PiB-PET) and examine the influence…Exploratory study of brain 5-HT4 receptor availability in early-stage Parkinson’s disease
Objective: To investigate possible alterations in the 5-HT4 serotonergic receptor in the brain of patients with PD at a relatively early stage, compared with healthy…PET Imaging of Presynaptic Terminals with [18F]SynVesT-1 in Premanifest Huntington’s Disease
Objective: To assess synapse loss in vivo in late premanifest Huntington’s disease (HD) subjects using [18F]SynVesT-1 positron emission tomography (PET). Background: Synaptic damage is believed…Caudate-Predominant Striatal Dopaminergic Deficits in bvFTD with Parkinsonism
Objective: To characterize the dopaminergic lesion pattern in behavioral variant frontotemporal dementia with parkinsonism (bvFTD-P) using dopamine transporter (DAT) positron emission tomography (PET), and to…DTI-ALPS index and its association with dopamine loss, brain metabolism, and motor and cognitive manifestations in Parkinson’s disease
Objective: This study aimed to investigate the clinical relevance of glymphatic dysfunction in Parkinson's disease (PD) by integrating the diffusion tensor imaging (DTI) analysis along…18F-FD4 PET Reveals α-Synuclein Deposition and Clinical Correlations in Parkinson’s Disease
Objective: This study aimed to determine the potential of a novel α-syn tracer, 18F-FD4 PET, to track regional α-synuclein deposition in PD and explore its…The Diagnostic Value of Dopaminergic-Glucose United PET Imaging in Parkinson’s disease
Objective: This study aimed to evaluate the diagnostic efficacy of DAT-FDG united PET imaging in differentiating PD from other parkinsonian disorders in real-world clinical settings…18F-FD4 PET Reveals α-Synuclein Deposition and Clinical Correlations in Multiple System Atrophy
Objective: This study aimed to determine the potential of 18F-FD4 PET to serve as an in vivo pathology mapping tool for MSA, providing initial proof-of-concept for its use in…In Vivo 18F-Florzolotau Tau PET Imaging in Parkinson’s Disease with and without Probable REM Sleep Behavior Disorder
Objective: To investigate the distribution and potential influence of tau pathology in Parkinson’s disease (PD) patients with and without prodromal REM sleep behavior disorder (pRBD),…FDG-PET-Based Machine Learning Differentiates Parkinson’s Disease from Other Neurodegenerative Disorders
Objective: To evaluate whether a fluorodeoxyglucose positron emission tomography (FDG-PET) machine learning (ML) framework can be extended to differentiate Parkinson's disease (PD) from other neurodegenerative…
- 1
- 2
- 3
- …
- 40
- Next Page »